Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 5:13:100109.
doi: 10.1016/j.ahjo.2022.100109. eCollection 2022 Jan.

Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling

Affiliations

Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling

Kardie Tobb et al. Am Heart J Plus. .

Abstract

Cardiovascular disease (CVD) is the leading cause of death in women, with underrepresented minority (URM) women experiencing the highest mortality rate. For decades, there has been an underrepresentation of women in CVD trials. Although more recent studies have increased the number of women enrolled in these trials, systematic reviews have demonstrated that this enrollment is still low. The National Institute of Health along with other agencies have boosted their efforts to increase enrollment of women and URM populations in CVD trials. Despite these efforts, there still remains a gap. This paper reviews the magnitude, implications and causes of the underrepresentation of women in CVD trials. A proposed multifaceted approach to solving this issue is also outlined in this commentary. Hopefully, implementation of these proposed solutions may facilitate the increase of women, including URM women, enrolled in CVD trials. It is anticipated that this will improve CVD outcomes in these patients.

Keywords: CAD; Cardiovasular disease; Clinical trials; Heart disease; Underrepresented minority populations; Women.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Calculation of the participation to prevalence ratio (PPR) An outline of the calculation of the participation to prevalence ratio (PPR) .

Similar articles

Cited by

References

    1. Virani S.S., et al. Heart disease and stroke statistics—2021 update. Circulation. 2021;143(8):e254–e743. - PubMed
    1. Solimene M.C. Coronary heart disease in women: a challenge for the 21st century. Clinics (Sao Paulo) 2010;65(1):99–106. - PMC - PubMed
    1. Ezekowitz J.A., et al. Is there a sex gap in surviving an acute coronary syndrome or subsequent development of heart failure? Circulation. 2020;142(23):2231–2239. - PubMed
    1. Kim C., et al. A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions. Clin. Cardiol. 2007;30(10):491–495. - PMC - PubMed
    1. Heron M. Deaths: leading causes for 2017. Natl. Vital Stat. Rep. 2019;68(6):1–77. - PubMed

LinkOut - more resources